Overview

• Pfizer agreed to offer Medicaid most‑favored‑nation prices and to align launch prices for new drugs with other high‑income countries, while joining the planned TrumpRx platform.
• TrumpRx is described as a federal portal that routes consumers to manufacturers’ direct‑sale sites for cash purchases, with officials saying they hope to launch it in early 2026.
• Pfizer and the White House touted discounts averaging about 50%, with some cuts reaching 80–85%, and officials cited examples including Eucrisa, Xeljanz and Zavzpret for direct buyers.
• Analysts say most insured patients and many Medicaid enrollees may see little immediate relief, key terms remain confidential, and officials do not expect consumer price changes until 2026.
• In exchange for pricing commitments, Pfizer received a three‑year exemption from prospective drug tariffs and pledged $70 billion in U.S. investment, as the administration presses other drugmakers under a 100% tariff threat starting Oct. 1 for those not building domestically.